Literature DB >> 7863965

Thrombin hypothesis of thrombus generation and vascular lesion formation.

L A Harker1, S R Hanson, M S Runge.   

Abstract

Thrombin plays a central role in vascular lesion formation. It is the principal mediator of thrombogenesis, which is interrupted when direct antithrombins (including hirudin and its synthetic peptide analogs), thrombin receptor antagonist peptides, or thrombin generation inhibitors (including active-site inhibited factor VIIa, recombinant tick anticoagulant peptide, and omega-3 fatty acids) are used to block thrombin. Thrombin is also a potent growth factor, initiating smooth muscle cell proliferation at injury sites. In baboons, this reaction is 80% reduced by hirudin (p < 0.01). Thrombin also plays a role in modulating the effects of other growth factors such as platelet-derived growth factor (PDGF). Thus, Phe-Pro-Arg-CH2Cl prevents expression in baboons of PDGF-A mRNA induced by vascular injury due to balloon angioplasty; untreated mechanical injury results in a 3-fold increase in PDGF-A mRNA expression. Thrombin also regulates inflammatory processes, inducing expression both of leukocyte adhesion molecules and of their counterreceptors by endothelium.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7863965     DOI: 10.1016/0002-9149(95)80004-c

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  8 in total

1.  Reexamination of the Thrombin Hypothesis: What We Have Learned from TIMI 9B and GUSTO IIb.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

2.  YD-3, a novel inhibitor of protease-induced platelet activation.

Authors:  C C Wu; S W Huang; T L Hwang; S C Kuo; F Y Lee; C M Teng
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

Review 3.  Thrombin receptor antagonists for the treatment of atherothrombosis: therapeutic potential of vorapaxar and E-5555.

Authors:  Sergio Leonardi; Pierluigi Tricoci; Richard C Becker
Journal:  Drugs       Date:  2010-10-01       Impact factor: 9.546

4.  Antithrombotic effects of BCH 2763, a new direct thrombin inhibitor, in a canine model of venous thrombosis.

Authors:  T B McClanahan; D P Ignasiak; P Juneau; C Finkle; P D Winocour; K P Gallagher
Journal:  J Thromb Thrombolysis       Date:  1999-06       Impact factor: 2.300

Review 5.  New approaches to anticoagulation in atrial fibrillation.

Authors:  Palle Petersen
Journal:  Curr Cardiol Rep       Date:  2004-09       Impact factor: 2.931

6.  Heparin cofactor II in atherosclerotic lesions from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study.

Authors:  Jill C Rau; Carolyn Deans; Maureane R Hoffman; David B Thomas; Gray T Malcom; Arthur W Zieske; Jack P Strong; Gary G Koch; Frank C Church
Journal:  Exp Mol Pathol       Date:  2009-09-09       Impact factor: 3.362

7.  Evaluation of plaque stability of advanced atherosclerotic lesions in apo E-deficient mice after treatment with the oral factor Xa inhibitor rivaroxaban.

Authors:  Qianxing Zhou; Florian Bea; Michael Preusch; Hongjie Wang; Berend Isermann; Khurrum Shahzad; Hugo A Katus; Erwin Blessing
Journal:  Mediators Inflamm       Date:  2011-06-07       Impact factor: 4.711

Review 8.  Serpins in thrombosis, hemostasis and fibrinolysis.

Authors:  J C Rau; L M Beaulieu; J A Huntington; F C Church
Journal:  J Thromb Haemost       Date:  2007-07       Impact factor: 5.824

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.